The company commenced the trial operations at this newly expanded plant on 22nd August.
The plant will produce the active pharmaceutical ingredients (API) for Malaria and anti-retroviral drugs.
The Company will be filing Drug Master File (DMF) for all its product with World Health Organization Geneva, it said.
DMFs are used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs to regulatory agencies.
It also plans to file DMF’s of certain API’s with United States Food & Drug Administration in the due course of time.
The total cost of the expansion was approximately Rs 30 Crore which was completed in time.
Mangalam Drugs & Organics Limited commenced in 1977 its manufacturing of Active Pharmaceutical Ingredients APIs, Intermediates at VAPI – Gujarat. It has a multi-product manufacturing facility on two locations, and an in-house R&D.